Affiliation:
1. Instituto Universitario CEMIC, Argentina
2. Hospital General Abel Zubizarreta, Argentina
Abstract
Abstract Alzheimer's disease (AD) patients suffer progressive cognitive, behavioral and functional impairment which result in a heavy burden to patients, families, and the public-health system. AD entails both direct and indirect costs. Indirect costs (such as loss or reduction of income by the patient or family members) are the most important costs in early and community-dwelling AD patients. Direct costs (such as medical treatment or social services) increase when the disorder progresses, and the patient is institutionalized or a formal caregiver is required. Drug therapies represent an increase in direct cost but can reduce some other direct or indirect costs involved. Several studies have projected overall savings to society when using drug therapies and all relevant cost are considered, where results depend on specific patient and care setting characteristics. Dementia should be the focus of analysis when public health policies are being devised. South American countries should strengthen their policy and planning capabilities by gathering more local evidence about the burden of AD and how it can be shaped by treatment options.
Subject
Cognitive Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Neurology,Sensory Systems
Reference48 articles.
1. Epidemiology of dementia;Arizaga RL,2005
2. Epidemiology of dementia;Fratiglioni L,2001
3. World Population Prospects: The 2008 Revision,2009
4. Global prevalence of dementia: a Delphi consensus study;Ferri CP;Lancet,2005
5. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina;Allegri RF;Int Psychogeriatr,2007
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献